Emmaus Life Sciences Reports Improved Quarterly Financial Results

Rhea-AI Summary

Emmaus Life Sciences (OTCQB: EMMA) reported Q3 2024 financial results with net revenues of $5.5 million, up 9% from Q3 2023, and net income of $1.8 million, a 2,626% increase. The company resumed inventory production in August, leading to improved quarterly performance. However, year-to-date net revenues decreased 41% due to earlier inventory shortages. Operating expenses decreased to $4.3 million in Q3 2024 from $4.8 million in Q3 2023. The launch of a competing generic L-Glutamine Oral Powder in July may impact future Endari sales. Cash position stood at $1.3 million as of September 30, 2024.

Positive

• Q3 net revenues increased by $0.5 million (9%) to $5.5 million
• Q3 net income grew by 2,626% to $1.8 million
• Operating expenses decreased by $0.5 million in Q3 2024
• Income from operations increased to $0.8 million in Q3 from $0.02 million in Q3 2023

Negative

• YTD net revenues decreased 41% compared to 2023
• Cash position declined to $1.3 million from $2.5 million at year-end 2023
• New generic competitor may impact future Endari sales
• YTD net loss of $4.7 million reported
• Full year results expected to be materially lower than 2023

TORRANCE, Calif., Nov. 19, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2024.

Highlights

"We are pleased to report that we were able to resume inventory production and fulfill back orders in August which led to increases of $0.5 million, or 9%, and $0.8 million, or over 3000%, in net revenues and income from operations, respectively, as compared to the same period a year earlier and net income of $1.8 million, an increase of 2,626% as compared to Q3 2023," commented Willis Lee, Chairman and Chief Executive Officer of Emmaus. "We expect net revenues and income from operations to stabilize in Q4.  Due to the inventory shortages we suffered earlier this year, net revenues for the nine months ended September 30 decreased 41% as compared to 2023 and we realized a loss from operations as compared to income from operations in the prior year. We expect results of operations for the full year to be materially lower than in 2023 for the same reason. Our Endari U.S. sales in Q3 may have been adversely affected by the launch in July of a competing generic L-Glutamine Oral Powder, and we are continuing to assess the possible effect on future Endari sales and net revenues and steps to bolster Endari sales," he added.

Financial and Operating Results

Net Revenues. Net revenues for the three months ended September 30 were $5.5 million, compared to $5.0 million in the same period in 2023.  The increase was due to an increase in sales in the Middle East North Africa region, partially offset by a decrease in U.S. sales which management attributes to competition from a generic product.

Operating Expenses. Total operating expenses for the three months were $4.3 million compared to $4.8 million in the comparable period in 2023. The decrease was due primarily to a decrease in clinical research organization expenses. Total operating expenses for the nine months were $13.8 million compared to $19.2 million in the comparable period in 2023. The decrease was due primarily to a $2.3 million decrease in payroll expenses including share-based compensation.

Income (Loss) From Operations. We realized income from operations for the three months of $0.8 million compared to income from operations of $0.02 million in the same period in 2023.  The increase was due to the $0.5 million increase in net revenues and $0.5 million decrease in operating expenses. We recorded a $1.3 million loss from operations for the nine months ended September 30, 2024 compared to $2.2 million of income from operations for the same period last year. The decrease resulted from the $9.2 million decrease in net revenues, partially offset by the $5.4 million decrease in operating expenses.

Other Income (Expense). The company realized other income of $1.0 million for the three months compared to $0.08 million in the same period in 2023. The increase was due primarily to decreases of $0.7 million in foreign exchange loss, $0.6 million in interest expense and $0.6 million in loss on debt extinguishment, partially offset by a decrease of $0.4 million in change in fair value of conversion feature derivative liabilities. Other expense for the nine months ended September 30, 2024 decreased to $3.3 million from $7.1 million in the same period in 2023 due primarily to an increase of $1.0 million in gain on restructured debt and decreases of $3.2 million in foreign exchange loss and $1.0 million in interest expenses, partially offset by an increase of $2.2 million  in change in fair value of conversion feature derivative liabilities from a $2.1 million decrease in 2023 to a $0.1 million increase in 2024.

Net Income (Loss). For the three months, the company realized net income of $1.8 million, or $0.03 per share based on approximately 63.9 million weighted average basic common shares, compared to net income of $0.07 million, or $0.00 per share based on approximately 53.6 million weighted average basic common shares in the comparable period in 2023. The increase in net income was primarily attributable to the increases in income from operations and other income. For the nine months ended September 30, 2024, the company reported a net loss of $4.7 million, or $0.07 per share, based on approximately 63.0 million weighted average basic common shares. This compares to a net loss of $4.9 million, or $0.09 per share, based on approximately 52.4 million weighted average basic common shares for the nine months ended September 30, 2023. The decrease was primarily due to the decreases of $5.4 million in operating expenses and $3.7 million in other expenses, partially offset by the decrease in net revenues of $9.2 million.

Liquidity and Capital Resources. At September 30, 2024, the company had cash and cash equivalents of $1.3 million, compared to $2.5 million at December 31, 2023. 

About Emmaus Life Sciences 
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman and is available on a named patient or early access basis in France, the Netherlands, and the Kingdom of Saudi Arabia, where Emmaus' application for marketing authorization is awaiting final action by the Saudi Food & Drug Authority. For more information, please visit www.emmausmedical.com.

About Endari® (prescription grade L-glutamine oral powder)
Endari®, Emmaus' prescription grade L-glutamine oral powder, was approved by the U.S. Food and Drug Administration (FDA) in July 2017 for treating sickle cell disease in adult and pediatric patients five years of age and older.

Indication
Endari® is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Important Safety Information
The most common adverse reactions (incidence >10 percent) in clinical studies were constipation, nausea, headache, abdominal pain, cough, pain in extremities, back pain, and chest pain.

Adverse reactions leading to treatment discontinuation included one case each of hypersplenism, abdominal pain, dyspepsia, burning sensation, and hot flash.

The safety and efficacy of Endari® in pediatric patients with sickle cell disease younger than five years of age has not been established.

For more information, please see full Prescribing Information of Endari® at: www.ENDARIrx.com/PI.

About Sickle Cell Disease
There are approximately 100,000 people living with sickle cell disease (SCD) in the United States and millions more globally. The sickle gene is found in every ethnic group, not just among those of African descent; and in the United States an estimated 1-in-365 African Americans and 1-in-16,300 Hispanic Americans are born with SCD.¹ The genetic mutation responsible for SCD causes an individual's red blood cells to distort into a "C" or a sickle shape, reducing their ability to transport oxygen throughout the body. These sickled red blood cells break down rapidly, become very sticky, and develop a propensity to clump together, which causes them to become stuck and cause damage within blood vessels. The result is reduced blood flow to distal organs, which leads to physical symptoms of incapacitating pain, tissue and organ damage, and early death.²

¹Source: Data & Statistics on Sickle Cell Disease – National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, December 2020.
²Source: Committee on Addressing Sickle Cell Disease – A Strategic Plan and Blueprint for Action -- National Academy of Sciences Press, 2020.

Forward-looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the expected net revenues for the full year 2024 and the possible effect on Endari sales and net revenues of the introduction of competing generic drugs. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including the company's need to restructure or refinance its existing indebtedness and raise additional funds from related-party loans, third-party loans or other financing to meet its current liabilities and fund its business and operations and doubt about the company's ability to continue as a going concern  and other factors disclosed in the company's Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q for the quarter ended September 30, 2024, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law. 

Company Contact:                                                   
Emmaus Life Sciences, Inc.                                       
Investor Relations                                                                                                 
(310) 214-0065                                               
IR@emmauslifesciences.com

 

(Financial Tables Follow)                 

 

Emmaus Life Sciences, Inc. Condensed Consolidated Statement of Operations and Comprehensive Income Loss (In thousands, except share and per share amounts)
	Three Months Ended September 30				Nine Months Ended September 30
	2024		2023		2024		2023
Revenues, Net	$5,478		$5,018		$13,361		$22,530
Cost of Goods Sold	394		214		892		1,151
Gross Profit	5,084		4,804		12,469		21,379
Operating Expenses	4,263		4,780		13,806		19,194
Income (Loss) from Operations	821		24		(1,337)		2,185
Total Other Income (Expense)	1,005		81		(3,345)		(7,074)
Net Income (Loss)	1,827		67		(4,705)		(4,942)
Comprehensive Income (Loss)	3,205		(1,322)		(6,561)		(3,826)
Net Income (Loss) Per Share	$0.03		$0.00		($0.07)		($0.09)
Weighted Average Common Shares Outstanding	63,865,571		53,637,554		63,025,296		52,414,903

 

Emmaus Life Sciences, Inc. Condensed Consolidated Balance Sheets (In thousands)
	As of
	September 30, 2024 (Unaudited)		December 31, 2023
Assets
Current Assets:
Cash and cash equivalents	$1,255		$2,547
Accounts receivable, net	4,938		4,010
Due from factoring of accounts receivable	54		1,514
Inventories, net	1,610		1,711
Prepaid expenses and other current assets	1,347		1,727
Total Current Assets	9,204		11,509
Property and equipment, net	49		59
Right of use assets	1,719		2,337
Investment in convertible bond	16,059		20,978
Other Assets	312		296
Total Assets	$27,343		$35,179
Liabilities and Stockholders' Deficit
Current Liabilities:
Accounts payable and accrued expenses	$18,707		$16,951
Conversion feature derivative, notes payable	523		451
Notes payable, current portion	7,915		8,215
Convertible notes payable, net of discount	16,205		16,383
Other current liabilities	20,781		19,507
Total Current Liabilities	64,131		61,507
Other long-term liabilities	16,993		21,428
Total Liabilities	81,124		82,935
Stockholders' Deficit	(53,781)		(47,756)
Total Liabilities & Stockholders' Deficit	$27,343		$35,179

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/emmaus-life-sciences-reports-improved-quarterly-financial-results-302310615.html

SOURCE Emmaus Life Sciences, Inc.

FAQ

What was Emmaus Life Sciences (EMMA) Q3 2024 revenue?

Emmaus Life Sciences reported Q3 2024 net revenues of $5.5 million, a 9% increase from $5.0 million in Q3 2023.

How much net income did Emmaus Life Sciences (EMMA) report in Q3 2024?

Emmaus Life Sciences reported Q3 2024 net income of $1.8 million, representing a 2,626% increase from $0.07 million in Q3 2023.

What is affecting Emmaus Life Sciences (EMMA) Endari sales in 2024?

Emmaus Life Sciences' Endari sales are being affected by the launch of a competing generic L-Glutamine Oral Powder in July 2024.

What was Emmaus Life Sciences (EMMA) cash position as of September 30, 2024?

Emmaus Life Sciences had cash and cash equivalents of $1.3 million as of September 30, 2024, down from $2.5 million at December 31, 2023.